Small Cell Lung Cancer Clinical Trials

45 studies are recruiting for small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors.…

   Stage

   Phase 1

   Ages

   19 and older

   Site

   University of Arkansas Medical School, Little Rock, Arkansas

   Locations

   20 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

2. Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

   Background: Small cell lung cancer (SCLC) is the deadliest form of lung cancer. Extrapulmonary neuroendocrine cancer (EPNEC) is a similar type of cancer that develops anywhere other than the lungs. EPNEC is also deadly. B7-H3 is a protein often found in SCLC and EPNEC tumor cells. Researchers can m…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07509034 on ClinicalTrials.gov

3. A Study of MGC026 in Participants With Advanced Solid Tumors

   The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalatio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The Angeles Clinic and Research Institute, Los Angeles, California

   Locations

   12 in total

   Run by

   MacroGenics

   See if you can join NCT06242470 on ClinicalTrials.gov

4. PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56

   The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT04199741 on ClinicalTrials.gov

5. A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

   Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-7…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Yale University School of Medicine /ID# 278181, New Haven, Connecticut

   Locations

   70 in total

   Run by

   AbbVie

   See if you can join NCT07155174 on ClinicalTrials.gov

6. SMARCA4/2 Inhibitor for POU2F3-Positive SCLC

   This is a single-arm, phase II clinical trial evaluating the efficacy and safety of FHD-286, a SMARCA4/2 inhibitor, in participants with POU2F3-expressing small cell lung cancer who have received at least one prior line of platinum-based therapy. All participants will receive FHD-286 orally once da…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT07551635 on ClinicalTrials.gov

7. A Study of Armored CAR T Cells in People With Cancer

   The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07783477 on ClinicalTrials.gov

8. Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

   Background: - Lung cancer is the leading cause of cancer-related death worldwide. It causes more than one million deaths every year. Researchers want to gather tissue samples from people with lung and thymic cancers to understand the disease better. This may lead to new ways to diagnose and treat i…

   Stage

   Not phased

   Ages

   18 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT02146170 on ClinicalTrials.gov

9. A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

   The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of California San Diego, La Jolla, California

   Locations

   165 in total

   Run by

   Zai Lab (Shanghai) Co., Ltd.

   See if you can join NCT07218146 on ClinicalTrials.gov

10. BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)

    The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Highlands Oncology Group, Springdale, Arkansas

    Locations

    62 in total

    Run by

    SystImmune Inc.

    See if you can join NCT07625644 on ClinicalTrials.gov

11. A Study of Hospital-at-Home for People Receiving Tarlatamab

    The purpose of this study is to find out whether a Hospital-at-Home (HaH) program is a more efficient way to monitor people's health after receiving tarlatamab than monitoring in the hospital (inpatient).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT06957314 on ClinicalTrials.gov

12. Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

    This study is being done to learn more about a new medicine called PF-08634404. The study team wants to understand how well PF-08634404 works when given alone or with chemotherapy . Chemotherapy is a type of cancer treatment that uses medicines to destroy cancer cells or stop them from growing. The…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    61 in total

    Run by

    Pfizer

    See if you can join NCT07476287 on ClinicalTrials.gov

13. A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

    Researchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also known as I-DXd) is a …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Colorado Anschutz Medical Campus ( Site 1110), Aurora, Colorado

    Locations

    48 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06780137 on ClinicalTrials.gov

14. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage

    Phase 1

    Ages

    12 and older

    Site

    University of San Diego Moores Cancer Center, La Jolla, California

    Locations

    76 in total

    Run by

    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

15. DESTINY-PANTUMOUR04

    This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

    Stage

    Not phased

    Ages

    18 to 130

    Site

    Research Site, Birmingham, Alabama

    Locations

    18 in total

    Run by

    AstraZeneca

    See if you can join NCT07124000 on ClinicalTrials.gov

16. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

    This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Precision NextGen Oncology, Beverly Hills, California

    Locations

    8 in total

    Run by

    Neonc Technologies, Inc.

    See if you can join NCT06047379 on ClinicalTrials.gov

17. A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

    Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, tolerability, and change in disease activi…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Birmingham Hematology and Oncology Associates d/b/a Alabama Oncology /ID# 280063, Birmingham, Alabama

    Locations

    72 in total

    Run by

    AbbVie

    See if you can join NCT07365241 on ClinicalTrials.gov

18. Study of Trilaciclib and Lurbinectidin

    Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina

    Locations

    2 in total

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT05578326 on ClinicalTrials.gov

19. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beverly Hills Cancer Center, Beverly Hills, California

    Locations

    37 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

20. Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer

    To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)

    Stage

    Not phased

    Ages

    18 and older

    Site

    Winship Cancer Institute, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT04342429 on ClinicalTrials.gov

21. Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

    The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small…

    Stage

    Phase 3

    Ages

    18 to 99

    Site

    University of Florida Health Cancer Center at Orlando Health, Orlando, Florida

    Locations

    9 in total

    Run by

    Amgen

    See if you can join NCT07778316 on ClinicalTrials.gov

22. Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

    The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    City of Hope Cancer Center Phoenix, Goodyear, Arizona

    Locations

    27 in total

    Run by

    Amgen

    See if you can join NCT07531095 on ClinicalTrials.gov

23. Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

    This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    2 in total

    Run by

    SciTech Development, Inc.

    See if you can join NCT06922539 on ClinicalTrials.gov

24. A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

    PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 immunotherapy agent. Up to one additional systemic anti-canc…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Southern Cancer Center, Daphne, Alabama

    Locations

    30 in total

    Run by

    Puma Biotechnology, Inc.

    See if you can join NCT06095505 on ClinicalTrials.gov

25. Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

    Although small cell lung cancer (SCLC) responds dramatically to initial platinum-based chemotherapy, recurrences are nearly universal. The addition of atezolizumab, an immune checkpoint inhibitor, to front-line chemotherapy has recently demonstrated an improvement in overall survival (OS) in extens…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07155200 on ClinicalTrials.gov